NLB Skladi, upravljanje premozenja, d.o.o. 13F: Exits NBIX Stake

NLB Skladi sold its entire stake in Neurocrine Biosciences, Inc. (NBIX), closing out its position of 7,000 shares. The complete exit was revealed in a Form 13F filing with the U.S. Securities and Exchange Commission on October 22, 2026.

NBIX Neurocrine Biosciences, Inc.

$141.31 ▲ +0.50% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in NLB Skladi's Neurocrine Biosciences Position

NLB Skladi completely parted ways with Neurocrine Biosciences, Inc. during the period, selling out of its entire holding of 7,000 shares. The fund held 7,000 shares prior to the reported transaction, leaving it with 0 shares after the sale. Because the fund closed its position entirely, it no longer owns any stock in the specialty drug maker.

Other Institutional Activity in Neurocrine Biosciences

Other large investors also made notable adjustments to their portfolios during recent reporting windows. Moody Lynn Lieberson & Walker closed out its entire position by selling 12,591 shares, leaving it with 0 shares valued at $0. Ninety One UK grew its holdings massively, adding 434,610 shares to end with 434,881 shares worth about $61,683,525. Livforsakringsbolaget Skandia, Omsesidigt trimmed its stake by 18,100 shares, finishing with 400 shares valued at about $56,736. Dodge & Cox Inc. grew its holdings by 123,425 shares, ending with 5,584,707 shares worth about $800,232,628. AQR Capital Management, LLC reduced its stake by 1,121,209 shares, leaving it with 3,818,037 shares valued at about $547,086,496.

Neurocrine Biosciences, Inc. Stock Up 0.2%

Neurocrine Biosciences stock recently traded around $141.59 as of October 23, 2026, down about 1.2% since closing at $143.29 on the day of the filing. The shares sit below both their 50-day and 200-day moving averages while trading well above their 52-week low of $122.14.

Recent Earnings

Neurocrine Biosciences reported trailing twelve month revenue of $3.37 billion alongside basic earnings of $6.82 per share. The company posted a net profit margin of 20.9% and a return on equity of 22.1%. The next earnings report is scheduled for November 2, 2026.

Insider Buying and Selling at Neurocrine Biosciences, Inc.

Chief Legal Officer Darin Lippoldt executed transactions earlier in the year, including purchasing 200 shares on June 26, 2026, at $81.49 for $16,298, and buying 9,800 shares on June 29, 2026, at $81.49 for $798,602. Lippoldt also sold 9,800 shares on June 29, 2026, at $170.16 for $1,667,612 under a planned arrangement, alongside another identical purchase of 9,800 shares at $81.49 on the same date.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. RBC Capital reiterated its Outperform rating with a $198 target on September 8, 2026. Morgan Stanley maintained its Equal-Weight rating and raised its target to $183 from $182 on September 11, 2026. UBS maintained a Buy rating while lowering its target from $231 to $214 on September 29, 2026. BMO Capital maintained a Market Perform rating and cut its target to $150 from $164 on October 12, 2026. Needham reiterated its Buy rating with a $204 target on October 16, 2026. The stock currently holds a consensus recommendation of strong buy from 29 analysts, with a mean price target of $206.54.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company headquartered in San Diego, California. The firm focuses on discovering and developing treatments for neurological, endocrine, and psychiatric conditions. Its marketed therapies address movement disorders and related health challenges.

Bottom Line

Investors will look toward the upcoming earnings release on November 2, 2026, for further insight into the company's financial health. Institutional turnover in the stock remains active as market participants adjust their holdings.